Atom Therapeutics Doses First Patient in Phase 2 Kidney Disease Trial
Atom Therapeutics said the first patient has been dosed in a Phase 2 trial of lingdolinurad (ABP-671) for chronic kidney disease with hyperuricemia.
Atom Therapeutics said the first patient has been dosed in a Phase 2 trial of lingdolinurad (ABP-671) for chronic kidney disease with hyperuricemia.